doi 10.1714/1640.17980 | Scarica il PDF (66,4 kb) G Ital Cardiol 2014;15(9):520 G Ital Cardiol 2014;15(2 Suppl 4):e56 titolo - split_articolo,controlla_titolo - art_titolo errata corrige testo - art_testo Cardiovascular (CV) safety of linagliptin in patients with type 2 diabetes (T2D): a pooled comprehensive analysis of prospectively adjudicated CV events in phase 3 studies G Ital Cardiol 2014;15(2 Suppl 4):e56 In merito all’abstract P65 sopraindicato, presentato al 45° Congresso Nazionale di Cardiologia dell’ANMCO (Firenze, 29-31 maggio 2014), gli autori comunicano l’errato inserimento del testo. Si riporta integralmente l’abstract corretto: P65 CARDIOVASCULAR (CV) SAFETY OF LINAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES (T2D): A POOLED COMPREHENSIVE ANALYSIS OF PROSPECTIVELY ADJUDICATED CV EVENTS IN PHASE 3 STUDIES Odd Erik Johansen1, Dietmar Neubacher2, Thomas Sech1, Sanjay Patel3, Hans Juergen Woerle1 1Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany, 2Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, 3Boehringer Ingelheim Ltd, Bracknell, UK Background and aims. Incidence of cardiovascular (CV) events is increased in patients with type 2 diabetes (T2D), but the potential for CV risk modulation with glucose-lowering therapies is debated. Materials and methods. We compared the incidence of CV events and CV mortality in patients with T2D treated with linagliptin (lina), a once-daily dipeptidyl peptidase (DPP)-4 inhibitor, with non-lina comparators (placebo or active; comp) in 19 double-blind RCTs (duration ≥12 weeks). CV events were prospectively adjudicated by a blinded independent expert committee. The primary endpoint was a composite of CV death, non-fatal stroke, non-fatal myocardial infarction, and hospitalisation for unstable angina pectoris. Other secondary and tertiary CV endpoints were also assessed. Results. Of 9459 patients, 5847 received lina (5 mg: 5687, 10 mg: 160) and 3612 comp (placebo: 2675, glimepiride: 775, voglibose: 162). The cumulative exposure (person years) was 4421.3 for lina and 3254.7 for comp. Changes (mean ± SEM) in HbA1c and weight, for lina and comp, respectively, were -0.68±0.01%/-0.27±0.02% and -0.1±0.1/+0.4±0.1 kg, whereas there were similar changes in systolic/diastolic blood pressure and lipids. In total, 60 primary events were reported in the lina group and 62 in the comp group (36 in the placebo and 26 in the active comp group). Rates of the primary endpoint (/1000 years at risk) were lower for lina (13.4%) than for the comp group (18.9%) in line with the hazard ratio (0.78) (Table). Conclusion. This updated pooled analysis of adjudicated CV events in a large Phase 3 programme continues to support that lina is not associated with an increased risk for CV events. Potential CV benefits with lina will be tested prospectively in more than 14,000 patients in the active-comparator (glimepiride) CAROLINA® trial (NCT01243424) and the placebo-controlled CARMELINATM trial.